Breast cancer patients’ use of certain dietary supplements before and during chemotherapy is linked to an increased risk of disease recurrence and death, a recent study involving Cleveland Clinic researchers has found.
After mastectomy, some patients are left without sensation in their breasts, which has negative implications for both safety and quality of life. Risal Djohan, MD, reviews anatomical targets for sensate reconstruction, including his DIEP flap technique.
Cleveland Clinic Cancer Center’s new CHIP Clinic will screen and monitor patients with potentially disease-causing somatic mutations called clonal hematopoiesis of indeterminate potential (CHIP) in blood or bone marrow cells.
The effectiveness of the combination of axillary reverse mapping and lymphaticovenous bypass in reducing lymphedema risk in breast cancer patients has made it the standard of care for women undergoing axillary lymphadenectomy at Cleveland Clinic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Indocyanine green (ICG) with near infrared (NIR) imaging is the standard for lymphatic mapping in Japan and Europe. A first-in-U.S. study compares it to 99mTc in breast cancer patients.
Can exercise intervention reduce racial and socioeconomic disparities in outcomes of breast cancer survivors over age 65? IMPROVE study is ongoing.
Adding the PI3K inhibitor alpelisib to antiestrogen therapy could be a major breakthrough in treating estrogen-receptor-positive metastatic or advanced breast cancers.
What’s the ideal radiation therapy approach after breast-conserving surgery for early-stage breast cancer? A new study compares cost-effectiveness of accelerated partial breast and hypofractionated whole breast irradiation.
With his new, five-year, $1.8 million award, Dr. Gong hopes to improve PARPi therapy by better understanding the mechanisms of resistance.
Multigene panel testing should be considered for all African-American women with triple-negative breast cancer regardless of their age or cancer history.